Boehringer, Dicerna in deal to develop NASH candidates

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) partnered with Boehringer Ingelheim GmbH (Ingelheim, Germany) to discover and develop RNAi-based therapeutics to treat non-alcoholic steatohepatitis (NASH) using Dicerna's GalXC platform.

Dicerna received $10 million upfront and is eligible for up to $191 million in milestones, as well as tiered royalties ranging from the high, single digit to low double digits...